From: Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Measure | Group (n) | Prevalence | PPV (95% CI) | Median OS, months (95% CI) | OS p-value | Median PFS, months (95% CI) | PFS p-value |
---|---|---|---|---|---|---|---|
Training Set (n = 84) | |||||||
CD8xPD-L1 | positive (26) | 0.31 | 0.42 (0.23–0.63) | 18.9 (8.2–NR) | 0.024 | 5.3 (2.6–9.3) | 0.00042 |
negative (58) | 0.69 | 0.09 (0.03–0.19) | 8.9 (4.1–12.9) | 1.4 (1.2–1.4) | |||
CD8+ cell density | high (32) | 0.38 | 0.34 (0.19–0.53) | 18.9 (12.9–NR) | 0.012 | 4.4 (1.4–7.6) | 0.00045 |
low (52) | 0.62 | 0.10 (0.03–0.21) | 8.8 (4.3–11.1) | 1.4 (1.2–2.3) | |||
PD-L1+ cell density | high (26) | 0.31 | 0.39 (0.20–0.59) | 18.9 (5.6–NR) | 0.071 | 4.7 (1.6–7.6) | 0.023 |
low (58) | 0.69 | 0.10 (0.04–0.21) | 8.9 (4.1–13.1) | 1.4 (1.3–1.7) | |||
PD-L1 TC | ≥25% (49) | 0.58 | 0.29 (0.17–0.43) | 17.9 (8.9–NR) | 0.018 | 2.8 (1.4–5.3) | 0.0048 |
< 25% (35) | 0.42 | 0.06 (0.01–0.19) | 7.6 (3.4–12.9) | 1.4 (1.2–1.4) | |||
Test Set (n = 79) | |||||||
CD8xPD-L1 | positive (33) | 0.42 | 0.36 (0.20–0.55) | 24.2 (14.5–NR) | 0.00011 | 7.3 (3.1–9.8) | 0.00095 |
negative (46) | 0.58 | 0.07 (0.01–0.18) | 6.5 (4.2–9.8) | 2.6 (1.4–3.9) | |||
CD8+ cell density | high (42) | 0.53 | 0.24 (0.12–0.40) | 20.3 (14.0–27.8) | 0.0044 | 5.5 (3.1–9.2) | 0.0054 |
low (37) | 0.47 | 0.14 (0.05–0.29) | 6.5 (3.6–9.8) | 2.5 (1.4–4.1) | |||
PD-L1+ cell density | high (29) | 0.37 | 0.38 (0.21–0.58) | 24.3 (6.5–NR) | 0.045 | 7.3 (2.6–9.2) | 0.087 |
low (50) | 0.63 | 0.08 (0.02–0.19) | 9.3 (6.0–15.5) | 2.8 (1.7–5.2) | |||
PD-L1 TC | ≥25% (47) | 0.59 | 0.28 (0.16–0.43) | 15.5 (7.7–24.2) | 0.19 | 4.8 (2.6–7.3) | 0.25 |
< 25% (32) | 0.41 | 0.06 (0.01–0.21) | 7.8 (5.7–15.5) | 2.8 (1.4–6.5) |